GSK plc 6-K, filed Feb 14, 2022
GSK plc (GSK)
6-K
2022-02-14
For: 2022-02-14
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on February 14, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
(the 'Company')
Transfer of Treasury Shares
On 10 February 2022, the Company
transferred 50,300,000 ordinary shares of 25 pence each
("Ordinary
Shares") that were held by the
Company in treasury ("Treasury
Shares") of which (a)
34,500,000 Ordinary Shares were transferred to the Company's Jersey
resident trust, the GlaxoSmithKline Employee Trust (the
"Jersey
Trust"), and (b) 15,800,000
Ordinary Shares were transferred to JPMorgan Chase Bank, N.A. the
depositary of the Company's American depositary receipts
("ADR") programme, to procure the issuance and transfer
of 7,900,000 ADRs of the Company to the GlaxoSmithKline (US)
Trust (the "US Trust"), such Ordinary Shares and those ADRs to be used
to satisfy awards granted under the Company's Deferred Annual Bonus
Plan, Performance Share Plan and Share Value Plan. The
consideration received from the trustee of the Jersey Trust, of
£16.208 per Ordinary Share, was funded by a loan from
GlaxoSmithKline Services Unlimited, and the consideration received
from the trustee of the US Trust of $44.260 per ADR, representing
$22.130 per Ordinary Share, was funded by a contribution to the US
Trust from GlaxoSmithKline LLC.
Following the transfer and as at 11 February 2022, the Company's
issued share capital consisted of 5,388,496,258 Ordinary Shares, of
which 304,905,950 were held as Treasury Shares.
Therefore, the total number of voting rights in the Company is
5,083,590,308. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.
V A Whyte
Company Secretary
14 February 2022
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
14, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|